BC Week In Review | Jun 17, 2013
Clinical News

DecisionDx-Melanoma test: Data

Data from an independent validation study of 92 melanoma tumor samples showed that patients with tumors classified as Class 1 - low risk of metastasis - by Castle Biosciences' DecisionDx-Melanoma test had a 5-year visceral metastatic-free survival...
Items per page:
1 - 1 of 1